Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Product Type
  5. Cell Therapy

Cell Therapy

Thumbnail
June 13, 2022

EHA 2022 – Crispr’s second off-the-shelf Car-T disappointment

Thumbnail
June 10, 2022

EHA 2022 – Caribou’s turn to run into allo Car-T relapses

The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.

Article image
Vantage logo
June 06, 2022

Asco 2022 – Adicet works hard to avoid the allo Car-T scenario

Long-awaited gamma-delta Car-T data sees the response rate fall to 20% at six months, but when is a relapse not a relapse?

Article image
Vantage logo
June 05, 2022

Asco 2022 – Carvykti casts a long shadow

Arcellx, Gracell and Oricell work hard to prove that there is still space for new Car-T therapies in multiple myeloma.

Article image
Vantage logo
June 01, 2022

Sernova gets under the skin

The company believes its new combination technology can make insulin injections a thing of the past.

Article image
Vantage logo
May 27, 2022

Iovance hammered as cell therapy disappoints

Lower – and shorter – efficacy add to serious doubts about the TIL therapy's future.

Article image
Vantage logo
May 17, 2022

Vertex’s halt does not deter Sernova and Evotec

Article image
Vantage logo
May 06, 2022

Asco 2022 – Affimed suffers withdrawal symptoms

Article image
Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

After a long wait, investors at last have early evidence that Nkarta’s Car-NK cells work – with a relatively clean safety profile to boot.

Article image
Vantage logo
April 10, 2022

AACR 2022 – Biontech’s cell therapy effort bears fruit at last

But it’s still far too early to tell whether combining Car-T with an mRNA vaccine might improve response durability.

Article image
Vantage logo
April 05, 2022

Venture funding stays strong despite the gloom

But how long can the money keep rolling in?

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.